Oxaliplatin Hikma

Oxaliplatin, the active ingredient in Oxaliplatin Hikma, is a platinum‑based chemotherapy presented as a sterile powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Hikma is used in the treatment of cancers that are part of the colorectal and gastrointestinal tumour pathway. - Colorectal cancer: improves survival by inhibiting tumor cell replication. - Gastric cancer: used in combination regimens to reduce tumor burden. - Pancreatic cancer: contributes to disease control when combined with other agents.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Peripheral neuropathy: tingling or numbness in the hands and feet. - Fatigue: persistent tiredness not relieved by rest. - Diarrhoea: loose stools that may require hydration. - Thrombocytopenia: reduced platelet count increasing bleed risk.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or difficulty breathing. - Hemolytic‑uremic syndrome: rare kidney injury with low platelets. - Cardiac arrhythmias: irregular heart rhythms observed during infusion.

When using Oxaliplatin Hikma, careful monitoring and patient assessment are essential. - Renal function: assess   - Cardiac   -   -  ullet   -  ullet   - Store  :  

The  

--- ---